Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome

The Korean Society of Haematology AML/MDS Working Party

    Research output: Contribution to journalLetterpeer-review

    2 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome'. Together they form a unique fingerprint.